The Effect of Probiotics (L. Helveticus, B. Longum, and B. Bifidum) on Immune Function and Digestive Health

NCT ID: NCT01709825

Last Updated: 2015-01-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

583 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-30

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if daily consumption of a probiotic in the period before, during and after academic exams will help maintain digestive and immune health and quality of life of undergraduate students.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A randomized, double-blinded, placebo-controlled trial will be used. Healthy full-time undergraduate students will be recruited from the University of Florida via flyers, emails, announcements, etc. Informed consent will be obtained and the inclusion/exclusion criteria will be reviewed to determine whether a participant qualifies for the study. All participants will be consented for the main six-week intervention and a subgroup (n=50/group) of these students will be consented to provide two stool samples.

Participants will provide saliva and stool samples (for the sub-group)during the pre-baseline week and during the week of final exams at approximately week 4. At the randomization visit, height, weight and age will be obtained. Participants will be stratified based on body mass index and randomized via sealed envelopes to one of four groups: Lactobacillus helveticus, Bifidobacterium longum ssp. Infantis, Bifidobacterium bifidum or the placebo (n=145/group). Participants will take the study provided capsule of probiotic or placebo daily for 6 weeks. Participants will receive daily questionnaires via email throughout the prebaseline week and the 6-week intervention. Daily questionnaires will ask about intake of the supplement, cold symptoms, and general health (i.e., new medications, doctor visits). Throughout the study, participants will also be asked to complete weekly questionnaires (inquiring about gastrointestinal symptoms and physical activity) and Quality of Life Questionnaires (administered during pre-baseline, final exam week and week 6 of the study).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sugar Pill

Sugar Pill will be taken as a capsule once daily for 6 weeks.

Group Type PLACEBO_COMPARATOR

Sugar Pill

Intervention Type DIETARY_SUPPLEMENT

Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.

Probiotic- Bifidobacterium bifidum

Bifidobacterium bifidum (Supplement A) will be taken as a capsule once daily for 6 weeks.

Group Type EXPERIMENTAL

Probiotic- Bifidobacterium Bifidum

Intervention Type DIETARY_SUPPLEMENT

Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.

Probiotic- Lactobacillus helveticus

Lactobacillus helveticus (Supplement B) will be taken as a capsule once daily for 6 weeks.

Group Type EXPERIMENTAL

Probiotic- Lactobacillus helveticus

Intervention Type DIETARY_SUPPLEMENT

Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.

Probiotic- Bifidobacterium longum ss. Infantis R0033

Bifidobacterium longum ss. Infantis R0033 (Supplement C)will be taken as a capsule once daily for 6 weeks.

Group Type EXPERIMENTAL

Probiotic- Bifidobacterium longum ss. Infantis R0033

Intervention Type DIETARY_SUPPLEMENT

Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotic- Bifidobacterium Bifidum

Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.

Intervention Type DIETARY_SUPPLEMENT

Sugar Pill

Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.

Intervention Type DIETARY_SUPPLEMENT

Probiotic- Lactobacillus helveticus

Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.

Intervention Type DIETARY_SUPPLEMENT

Probiotic- Bifidobacterium longum ss. Infantis R0033

Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bifidobacterium bifidum Supplement A Sucrose Lactobacillus helveticus Supplement B Bifidobacterium longum ss. Infantis R0033 Supplement C

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

To participate in the study you must:

* be 18 years of age or older.
* be a healthy full-time undergraduate at the University of Florida.
* be willing to complete daily questionnaires form via computer.
* be willing to discontinue any immune-enhancing dietary supplements (e.g., prebiotics and fiber supplements, probiotics, echinacea, fish oil, vitamin E \>400% of the RDA or \>60 mg/day).
* be willing to take the probiotic capsule daily of 6 weeks.
* have had at least one cold in the last 12 months.
* have at least 1 final during the scheduled exam week.
* have daily access to the Internet.

Exclusion Criteria

To participate in the study you must NOT:

* be a current smoker.
* have chronic allergies involving the upper respiratory tract.
* have had immunosuppressive illness or treatment within the last year.
* have received antibiotic therapy in the past two months.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lallemand Human Nutrition

UNKNOWN

Sponsor Role collaborator

University of Florida

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bobbi Langkamp-Henken, PhD, RD

Role: PRINCIPAL_INVESTIGATOR

University of Florida

Wendy Dahl, PhD, RD

Role: PRINCIPAL_INVESTIGATOR

University of Florida

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Florida

Gainesville, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Langkamp-Henken B, Rowe CC, Ford AL, Christman MC, Nieves C Jr, Khouri L, Specht GJ, Girard SA, Spaiser SJ, Dahl WJ. Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015 Feb 14;113(3):426-34. doi: 10.1017/S0007114514003997. Epub 2015 Jan 21.

Reference Type RESULT
PMID: 25604727 (View on PubMed)

Culpepper T, Christman MC, Nieves C Jr, Specht GJ, Rowe CC, Spaiser SJ, Ford AL, Dahl WJ, Girard SA, Langkamp-Henken B. Bifidobacterium bifidum R0071 decreases stress-associated diarrhoea-related symptoms and self-reported stress: a secondary analysis of a randomised trial. Benef Microbes. 2016 Jun;7(3):327-36. doi: 10.3920/BM2015.0156. Epub 2016 Feb 3.

Reference Type DERIVED
PMID: 26839075 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

403-2012

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Probiotic Detection and Persistence Study
NCT04065503 COMPLETED EARLY_PHASE1
Probiotics to Promote Intestinal Health
NCT02046512 COMPLETED PHASE4